Remember meForgot password?
    Log in with Twitter

Valeant Pharmaceuticals News

Hillary Clinton vows to go after Valeant Pharmaceuticals

Valeant Pharmaceuticals International Inc. saw a drop in shares by as much as 21 percent on Monday after it revealed the Canadian company was being investigated by the Securities and Exchange Commission. Now it has Hillary Clinton to contend with.

Valeant's low libido drug for women is not off to a good start

Women apparently don't have as many problems as men in the sack, because the highly touted "female Viagra" pill for women, Addyi, is having sales as slow as, well, molasses in January.

Round-up of the week's pharmaceutical industry news

Digital Journal has assessed the key developments in the pharmaceutical sector this week and brings you the latest company mergers, suspect business practices, and ‘structural adjustments.’

Op-Ed: No COLA increase coming for Social Security recipients

The government announced there will be no cost-of-living (COLA) increase in their benefits next year. The difference would mean an average of a little more than $500 a year in Social Security benefits.

Canadian Valeant Pharmaceuticals to buy Sprout Pharmaceuticals

Canada giant Valeant Pharmaceuticals is to purchase Sprout Pharmaceuticals,manufacturer of the first FDA-approved treatment for low sexual desire in women.

Search Digital Journal Archives

Set up a news alert for

Valeant Pharmaceuticals

Valeant Pharmaceuticals Image

J. Michael Pearson  CEO of the publicly traded Montreal-based Valeant Pharmaceuticals International.
J. Michael Pearson, CEO of the publicly traded Montreal-based Valeant Pharmaceuticals International.
Illustration by Digital Journal / Photo inset Valeant

Latest News
Top News